

Prescribing and Formulary Panel

Minutes of a meeting held at 5pm Tuesday June 14th 2022 Oak MDT Room

Present

Geraldine O’Riordan, Prescribing Advisor and Chair

Douglas Wilson, Queens Road Medical Practice

Mike McCarthy, Healthcare Group

Peter Gomes, Medical Specialist Group

Paul Williams, Island Health Medical Practice

Apologies

Tom Saunders, Medical Specialist Group

Andrew Ward, PEH Pharmacy Manager

Absent

Nikki Brink

Draft Minutes

The Draft minutes of the May 2022 meeting were approved.

- **New Drugs**

Aztreonam Lysine

The product has been requested for a patient with advanced CF lung disease whose sputum is chronically colonised with *Pseudomonas aeruginosa*. The patient has been unable to tolerate inhaled colistimethate sodium or tobramycin in the past. The UK consultant wishes to try nebulised aztreonam lysine which is on the hospital formulary for NHS patients. After a brief discussion it was agreed to approve this product when recommended by tertiary centres for CF patients when tobramycin or colistimethate are not effective or not tolerated and when it is prescribed in Southampton and delivered by Homecare with the patient’s other treatment.

Action : GOR

- **Minor and/or cost-neutral additions to the Prescribing List approved**

1.Cathflo® Actlyse® (alteplase) is used to unblock central lines including for haemodialysis patients. It is out of stock until 2024 and the other appropriate alteplase products do not have enough supply capacity. The DM and D list cost price is £225 for a box of 5.

TAP has requested an alternative product, TauroLock U25000 (urokinase) of which there is sufficient capacity and which costs £250 per box of 5 with a carriage charge of £50 per box. This was approved for addition to the PEH formulary.

2.The following products to be changed to “For PEH Pharmacy Dispensing Only” on the Prescribing List, which will not be delivered to retail pharmacies.

- Etanercept (but not the biosimilar)
- Tocilizumab
- Nintendanib

Action: GOR

- **New NICE TAs**

None

- **Black Triangle Drugs**

New list attached for information. GOR said that the new NICE TAs are all “Black triangle drugs” and that all suspected adverse effects should be reported.

- **New NMPs**

None

- **AOB**

Estimate of patient numbers on high numbers of regular repeat medication every month for Primary Care review

GOR thanked the practices for their on-going work on the above.

Action: GOR

- **Date of next meeting:** Tuesday July 12th 5pm, Oak MDT Meeting Room